|
INDICATIONS
|
PATADAY™ solution is indicated for the treatment of ocular itching associated with allergic conjunctivitis.
|
|
MECHANISM OF ACTION
|
Combo Mast Cell Stabilizer / Anti H1
|
|
MICROBIOLOGY
|
Olopatadine is a mast cell stabilizer and a histamine H1 antagonist. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
|
|
CONTRAINDICATIONS & WARNINGS
|
Hypersensitivity to any components of the product.
|
|
PEDIATRIC USE
|
Safety and effectiveness in pediatric patients below the age of 2 years have not been established.
|
|
PREGNANCY
|
Category C Teratogenic effects: Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 150,000 times the MROHD and rabbits treated at 400 mg/kg/day, or approximately 100,000 times the MROHD, during organogenesis showed a decrease in live fetuses. In addition, rats treated with 600 mg/kg/day of olopatadine during organogenesis showed a decrease in fetal weight. Further, rats treated with 600 mg/kg/day of olopatadine during late gestation through the lactation period showed a decrease in neonatal survival and body weight. There are, however, no adequate and well- controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.
|
|
NOTE
|
qDay dosing of Pataday 0.2% solution is as effective as BID dosing of Pataday 0.1% solution. (Effective for 24 hrs)
|
